ParaGard® does not protect against HIV/AIDS or other sexually transmitted infections. ParaGard® must not be used by women who are or may be pregnant; have acute pelvic inflammatory disease (PID) or current behavior suggesting a high risk for PID; have had a postpregnancy or postabortion uterine infection in the past 3 months; have cancer of the uterus or cervix; have an infection in the cervix; have an allergy to any component; or have Wilson's disease. The most common side effects of ParaGard® are heavier and longer periods and spotting between periods; for most women, these typically subside after 2 to 3 months. If a woman misses her period, she must be promptly evaluated for pregnancy. Some possible serious complications that have been associated with intrauterine contraceptives, including ParaGard®, are PID, perforation of the uterus, and expulsion.

References:

  1. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 3rd ed. Geneva, Switzerland: World Health Organization, Reproductive Health and Research; 2004.
  2. Sivin I, Stern J, Diaz S, et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Am J Obstet Gynecol. 1992;166(4):1208-1213.
  3. Vessey MP, Lawless M, McPherson K, Yeates D. Fertility after stopping use of intrauterine contraceptive device.
    Br Med J. 1983;286(6359):106.
  4. Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility—follow-up after participation in a randomized clinical trial. Contraception. 2007;75(2):88-92.
  5. Trussell J, Leveque JA, Koenig JD, et al. The economic value of contraception: a comparison of 15 methods.
    Am J Public Health. 1995;85(4):494-503.